About Samsara BioCapital
Samsara BioCapital is a venture capital firm founded in 2016. It is primarily based out of Palo Alto, United States. As of Apr 2026, Samsara BioCapital is an active investor, having invested in 96 companies, with 9 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series B round of Sidewinder Therapeutics Overall, Samsara BioCapital portfolio has seen 32 IPOs and 18 acquisitions including key companies like SpringWorks Therapeutics, Recursion Pharmaceuticals and Fulcrum Therapeutics. A lot of funds co-invest with Samsara BioCapital, with names like RA Capital Management sharing a substantial percentage of its portfolio. Samsara BioCapital has team of 30 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 6 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Samsara BioCapital's List of Top Investments
Samsara BioCapital has a portfolio of 96 companies. Their most notable investments are in Normunity and Psithera.Their portfolio spans across United States, United Kingdom, Canada and 5 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 3 other sectors, across stages such as Series B, Series A and 6 more. Here is the list of top investments by Samsara BioCapital:Developer of small molecule therapeutics for treating cancer and rare diseases. The company's lead drug Nirogacestat (PF-03084014), a gamma-secretase inhibitor that helps in treating non-metastatic tumors of connective tissue cells. The second candidate is a MEK 1/2 inhibitor, PF-0325901, for the genetic disorder NF1, one of three genetic conditions known as neurofibromatosis. The 3rd candidate, senicapoc (PF-05416266), also targets a rare condition, hereditary xerocytosis characterized by dehydrated red blood cells.
Key facts about SpringWorks Therapeutics
- Founded Year: 2017
- Location: New York City (United States)
- Annual Revenue: $192M as on Dec 31, 2024
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $230M
- Employee Count: 401 as on Mar 31, 2026
- Investors: BVF Partners, Boxer Capital and 17 Others
- Latest Funding Round: Post IPO, Sep 07, 2022, $*****
- Highlight: Acquired
AI-enabled drug discovery and development platform for novel therapeutics. It focuses on identifying new targets and designing optimized molecules. The platform utilizes biological and chemical datasets, machine learning models, and a supercomputer to accelerate the discovery of medicines. It aims to improve the speed and efficiency of drug development for conditions with high unmet needs, including cancers and rare diseases. The company also forms strategic partnerships to expand its impact on patients.
Key facts about Recursion Pharmaceuticals
- Founded Year: 2013
- Location: New York (United States)
- Annual Revenue: $58.8M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $452M
- Employee Count: 515 as on Jan 31, 2024
- Investors: HTIF, Square 1 Bank and 46 Others
- Latest Funding Round: Post IPO, Jul 12, 2023, $*****
- Highlight: Public
Fulcrum Therapeutics is focused on discovering and developing small molecules that modulate the on/off control mechanisms that regulate genes. The Fulcrum product engine integrates insights from four scientific disciplines (Gene Regulation, Human Genetics and Disease, Cell Biology, and Screening and Computation) to identify novel drug targets and develop breakthrough medicines. The early focus of Fulcrum’s product engine is on two severe genetic diseases: Fragile X syndrome (FXS) and a form of muscular dystrophy called facioscapulohumeral muscular dystrophy (FSHD). Each disease arises from a single gene mutation that creates an error in gene regulation. In the case of Fragile X, the silencing of the FMR1 gene eliminates the cell’s ability to make a protein needed for brain function. In FSHD, the precipitating event is the activation of a gene called DUX4 that should be silent in adulthood. This activation leads to muscle wasting as cells die.
Key facts about Fulcrum Therapeutics
- Founded Year: 2015
- Location: Cambridge (United States)
- Annual Revenue: $80M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $115M
- Employee Count: 74 as on Mar 31, 2026
- Investors: Boxer Capital, Fidelity Investments and 15 Others
- Latest Funding Round: Post IPO, Jun 10, 2020, $*****
- Highlight: Public
Developer of antibody-based therapeutics for cancer therapy. The company uses cell-free protein synthesis platform XpressCF technology led to the discovery of STRO-001 and STRO-002, for B-cell malignancies, ovarian and endometrial cancers.
Key facts about Sutro Biopharma
- Founded Year: 2003
- Location: United States
- Annual Revenue: $559K as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $175M
- Employee Count: 223 as on Mar 31, 2026
- Investors: Amgen Business Development, Citadel and 17 Others
- Latest Funding Round: Series E, Jul 26, 2018, $*****
- Highlight: Public
5. ElevateBio
Provider of transnational research for portfolio of cell and gene therapy. It offers transformative therapy along with other translational research like process development, cGMP manufacturing, clinical development, regulatory affairs, and commercial operations.
Key facts about ElevateBio
- Founded Year: 2018
- Location: Cambridge (United States)
- Stage: Series D
- Total Funding till date: $1.25B
- Employee Count: 493 as on Mar 31, 2026
- Investors: Fidelity Investments, Citadel and 16 Others
- Latest Funding Round: Series D, May 24, 2023, $*****
- Highlight: Editors' Pick
Samsara BioCapital's Year-on-Year Investment Trends
Samsara BioCapital has invested in 96 companies over the last 9 years, with an average of 10 new investments annually in the last 5 years. In 2025, it made 11 investments, while as of Apr 2026, it has made 5 investments in this year. Its most recent first time investment was in Sidewinder Therapeutics and most recent follow-on round was in Primmune Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 4 | 1 | 5 |
2025 | 7 | 4 | 11 |
2024 | 9 | 7 | 16 |
2023 | 4 | 9 | 13 |
2022 | 10 | 8 | 18 |
2021 | 24 | 3 | 27 |
2020 | 19 | 6 | 25 |
2019 | 14 | 0 | 14 |
2018 | 3 | 0 | 3 |
2017 | 2 | 0 | 2 |
Samsara BioCapital's Investments by Stage
Samsara BioCapital has made 31 investments in Series B stage with an average round size of $91.7M, 30 investments in Series A stage with an average round size of $87.9M and 16 investments in Post IPO stage with an average round size of $109M.Stage of entry | No. of Investments |
|---|---|
Series B | 31 |
Series A | 30 |
Post IPO | 16 |
Series C | 8 |
Series D | 6 |
Others | 5 |
Note: We have considered here, only first round of investments
Samsara BioCapital's Investments by Sector
Samsara BioCapital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Healthcare, Sustainability Tech and Enterprise Applications. Notably, it has invested in 88 Tech companies, 86 Enterprise (B2B) companies, 5 Software companies and at least 3 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 88 |
High Tech | 13 |
Healthcare | 7 |
Sustainability Tech | 4 |
Enterprise Applications | 3 |
Others | 5 |
Note: We have considered here, only first round of investments
Samsara BioCapital's Investments by Geography
Samsara BioCapital has made most investments in United States (80), followed by United Kingdom where it has made 6 investments.Country | No. of Investments |
|---|---|
United States | 80 |
United Kingdom | 6 |
Canada | 3 |
France | 2 |
Austria | 1 |
Others | 3 |
Note: We have considered here, only first round of investments
Samsara BioCapital's recent investments
Samsara BioCapital has made 5 investments in 2026 so far. Sidewinder Therapeutics and Ambrosia Biosciences are the latest among them.Here are the most recent investments by Samsara BioCapital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Apr 08, 2026 | United States | Series B | 8798 | ||
Mar 31, 2026 | United States | Series B | 4292 | ||
Jan 26, 2026 | United States | Series B | 1034 | [+1] | |
Jan 08, 2026 | United States | Series F | 5320 | [+18] | |
Jan 08, 2026 | United States | Series B | 4064 | [+10] |
IPOs and Publicly Listed companies in Samsara BioCapital's Portfolio
32 of Samsara BioCapital's portfolio companies have become public. Alamar Biosciences got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Apr 2026 at marketcap of $1.14B and SpyGlass got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $511M.Here are Samsara BioCapital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 17, 2026 | Sep 08, 2021 | Series B | 8495 | |
Feb 06, 2026 | Jul 10, 2023 | Series C | 4337 | |
Oct 25, 2024 | Jan 27, 2022 | Series A | 3377 | |
Oct 11, 2024 | Jun 02, 2022 | Series A | 8356 | |
Oct 07, 2024 | Mar 03, 2021 | Series B | 5792 |
Acquired companies in Samsara BioCapital's Portfolio
18 companies from Samsara BioCapital's portfolio have been acquired. The most recent acquisition was Centessa Pharmaceuticals in Mar 2026 by Lilly for $*****.Here are Samsara BioCapital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 31, 2026 | Feb 16, 2021 | Series A | 2345 | |
Mar 27, 2026 | Oct 13, 2025 | Series A | 1482 | |
Feb 23, 2026 | Mar 26, 2021 | Series C | 8789 | |
Oct 24, 2025 | Feb 05, 2024 | Post IPO | 6036 | |
Jul 09, 2025 | Jul 17, 2020 | Post IPO | 5066 |
Team profile of Samsara BioCapital
Samsara BioCapital has a team of 30 members including 1 Partner, 10 Venture Partners and 2 Principals located in United States and United Kingdom. Samsara BioCapital's team does not sit on the board of any company as of now.Here is a list of top team members in Samsara BioCapital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Francisco | - | ||
Venture Partner | Cambridge | - | ||
Venture Partner | New York City | - | ||
Venture Partner | Bourne End | - | ||
Venture Partner | Carlsbad | - | ||
Venture Partner | San Francisco | - | ||
Venture Partner | Lansdale | - | ||
Venture Partner | Palo Alto | - | ||
Venture Partner | San Francisco | - | ||
Venture Partner | San Francisco | - |
Co-investors of Samsara BioCapital
Over the past 9 years, 645 investors have co-invested in Samsara BioCapital's portfolio companies. This includes funds and angels.
- Invested before Samsara BioCapital: Orbimed, BVF Partners and 213 others have invested in rounds before Samsara BioCapital. There are 8 companies where Orbimed has invested before Samsara BioCapital and 7 companies where BVF Partners has invested before Samsara BioCapital.
- Top Co-investors of Samsara BioCapital: 266 investors entered a company along with Samsara BioCapital. These include investors like RA Capital Management (15 companies).
- Invested after Samsara BioCapital: A total of 164 investors have invested in Samsara BioCapital's portfolio after their investments. Top Investors include Janus Henderson Investors (6 companies), RA Capital Management (5 companies) and Orbimed (4 companies).
Recent News related to Samsara BioCapital
•
•
Colorado biotech Ambrosia lands $100M for oral GLP-1Endpoints•Mar 31, 2026•Ambrosia Biosciences, Blue Owl, Deep Track Capital, Samsara BioCapital and 8 others
•
•
•
Parabilis gets $305M to conquer 'undruggable' proteins after early successEndpoints•Jan 08, 2026•Parabilis Medicines, Johnson & Johnson, Frazier Life Sciences, Rock Springs Capital and 19 others
•
•
Link Cell Therapies Announces $60M Series A FinancingMassinvestor•Dec 15, 2025•Link Cell Therapies, Johnson & Johnson, Samsara BioCapital, Wing Venture Capital
•
PsiThera, Roivant spin-out, secures $47.5M for oral I&I drugsEndpoints•Dec 10, 2025•Psithera, Eurofarma, Roivant Sciences, Lightstone Ventures and 1 other
•
•
Rani Therapeutics Announces Oversubscribed $60.3 Million Private PlacementGlobeNewswire•Oct 17, 2025•Rani Therapeutics, Samsara BioCapital
